Multidimensional approaches in dealing with prostate cancer

被引:4
作者
Ali, Safdar [1 ]
Ali, Sher [1 ]
机构
[1] Natl Inst Immunol, Mol Genet Lab, Aruna Asaf Ali Marg, New Delhi 110067, India
关键词
linkage; androgen; estrogen; radiation;
D O I
10.1016/j.gene.2007.11.020
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Prostate cancer is one of the most prevalent malignancies worldwide affecting the human male population. Different case-control, cohort or twin studies and segregation analyses point towards the presence of prostate cancer-susceptibility genes in the population. The studies have shown linkage of prostate susceptibility genes to multiple loci on chromosome 1 and single locus each on chromosomes 4, 8, 16, 17, 19, 20 and X chromosome. However, differences right from the mode of inheritance (autosomal dominant or X-linked recessive) to the target genes exist. There have been reports supporting no or weak linkage to these loci as well. Also, region (environmental factors), age and dietary habits have implications in different aspects of the disease. The important targets for treating prostate cancer are androgens and estrogen (synthesized from androgens by the action of enzyme aromatase) owing to their involvement in development and progression of prostate cancer. Further, prostate gland needs androgens (male hormones) for its normal maintenance and functioning. Besides, radiation therapy and surgical methods have also been used. The emerging areas include identifying and preparing successful vaccines from candidate peptides and gene therapy in several forms. This review deals with the paradox of linkage analyses and the various approaches in practice for treatment and management of prostate cancer. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 87 条
[31]  
He QH, 2003, DIS MARKERS, V19, P69
[32]  
Hiramatsu M, 1997, PROSTATE, V31, P118
[33]   Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study [J].
Hsieh, CL ;
Oakley-Girvan, I ;
Gallagher, RP ;
Wu, AH ;
Kolonel, LN ;
Teh, CZ ;
Halpern, J ;
West, DW ;
Paffenbarger, RS ;
Whittemore, AS .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (24) :1893-1894
[34]   A genome screen of families with multiple cases of prostate cancer: Evidence of genetic heterogeneity [J].
Hsieh, CL ;
Oakley-Girvan, I ;
Balise, RR ;
Halpern, J ;
Gallagher, RP ;
Wu, AH ;
Kolonel, LN ;
O'Brien, LE ;
Lin, IPG ;
Van den Berg, DJ ;
Teh, CZ ;
West, DW ;
Whittemore, AS .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (01) :148-158
[35]   Cancer statistics, 2006 [J].
Jemal, A ;
Siegel, R ;
Ward, E ;
Murray, T ;
Xu, JQ ;
Smigal, C ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2006, 56 (02) :106-130
[36]   Localizing prostate cancer in the presence of postbiopsy changes on MR images: Role of proton MR spectroscopic imaging [J].
Kaji, Y ;
Kurhanewicz, J ;
Hricak, H ;
Sokolov, DL ;
Huang, LR ;
Nelson, SJ ;
Vigneron, DB .
RADIOLOGY, 1998, 206 (03) :785-790
[37]   Lack of Association between Y-Chromosomal Haplogroups and Prostate Cancer in the Korean Population [J].
Kim, Wook ;
Yoo, Tag-Keun ;
Kim, Sung-Joo ;
Shin, Dong-Jik ;
Tyler-Smith, Chris ;
Jin, Han-Jun ;
Kwak, Kyoung-Don ;
Kim, Eun-Tak ;
Bae, Yoon-Sun .
PLOS ONE, 2007, 2 (01)
[38]   The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the γ-tubulin complex [J].
Korver, W ;
Guevara, C ;
Chen, Y ;
Neuteboom, S ;
Bookstein, R ;
Tavtigian, S ;
Lees, E .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (03) :283-288
[39]  
KOSARY CL, 1995, NIH PUB, V96, P2789
[40]   Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy [J].
Kruit, WHJ ;
Stoter, G ;
Klijn, JGM .
ANTI-CANCER DRUGS, 2004, 15 (09) :843-847